ATAC - Endometrial Sub-Protocol

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Tamoxifen

Criteria

Inclusion Criteria:

• Patients eligible for entry into the main ATAC trial (1033IL/0029)

• Not received any previous tamoxifen, for whatever reason

• Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years

• No previous endometrial ablation

Exclusion Criteria:

• Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)